Zavesca Actelion Pharmaceuticals - Treatment for Type 1 Gaucher Disease
Zavesca is in a class of drugs known as substrate reduction therapy
(SRT), which reduces the amount of glycosphingolipid (GSL)
production. Zavesca is indicated for the treatment of adult
patients with mild to moderate type 1 Gaucher disease for whom
enzyme replacement therapy is not a therapeutic option.
Posted: July 2003